FHIT Polyclonal Antibody - Citations

FHIT Polyclonal Antibody - Citations

View additional product information for FHIT Polyclonal Antibody - Citations (719000)

Showing 4 product Citations

Citations & References
Abstract
Alterations of the fragile histidine triad gene, FHIT, and its encoded products contribute to testicular germ cell tumorigenesis.
AuthorsKraggerud SM, Aman P, Holm R, Stenwig AE, Fosså SD, Nesland JM, Lothe RA,
JournalCancer Res
PubMed ID11809703
The fragile histidine triad (FHIT) gene, located within chromosome arm 3p, is a potential target for testicular tumorigenesis. In the present study, 62 primary testicular germ cell tumors were analyzed for allelic imbalance (AI) at 10 loci mapping to chromosome bands 3p14.1-21.1. Twenty-seven tumors (44%) showed AI at one or ... More
Fhit regulates EMT targets through an EGFR/Src/ERK/Slug signaling axis in human bronchial cells.
AuthorsJoannes A, Grelet S, Duca L, Gilles C, Kileztky C, Dalstein V, Birembaut P, Polette M, Nawrocki-Raby B,
JournalMol Cancer Res
PubMed ID24464917
In many cancers, including lung carcinomas, Fragile histidine triad (Fhit) is frequently decreased or lost. Fhit status has recently been shown to be associated with elevated in vitro and in vivo invasiveness in lung cancer. Tumor cell invasion is facilitated by epithelial-mesenchymal transition (EMT), a process by which tumor cells ... More
Loss of fragile histidine triad protein in human hepatocellular carcinoma.
AuthorsZhao P, Song X, Nin YY, Lu YL, Li XH,
JournalWorld J Gastroenterol
PubMed ID12800227
'To investigate the expression of fragile histidine triad (FHIT) gene protein, Fhit, which is recently thought to be a candidate tumor suppressor. Abnormal expression of fragile histidine triad has been found in a variety of human cancers, but little is known about its expression in human hepatocellular carcinogenesis and evolution. ... More
Protein expression profiling identifies subclasses of breast cancer and predicts prognosis.
AuthorsJacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, Adélaïde J, Koki A, Houvenaeghel G, Hassoun J, Maraninchi D, Viens P, Birnbaum D, Bertucci F,
JournalCancer Res
PubMed ID15705873
Breast cancer is a heterogeneous disease whose evolution is difficult to predict by using classic histoclinical prognostic factors. Prognostic classification can benefit from molecular analyses such as large-scale expression profiling. Using immunohistochemistry on tissue microarrays, we have monitored the expression of 26 selected proteins in more than 1,600 cancer samples ... More